Literature DB >> 24796432

Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs.

Tiejun Li1, Meihua Wu, York Yuanyuan Zhu, Jianxin Chen, Li Chen.   

Abstract

RNA interference (RNAi) has been proven in recent years to be a newly advanced and powerful tool for development of therapeutic agents toward various unmet medical needs such as cancer, in particular, a great attention has been paid to the development of antineoplastic agents. Recent success in clinical trials related to RNAi-based therapeutics on cancer and ocular disease has validated that small interfering RNAs (siRNAs) constitute a new promising class of therapeutics. Currently, a great wealth of multi-target based siRNA structural modifications is available for promoting siRNA-mediated gene silencing with low side effects. Here, the latest developments in RNAi-based therapeutics and novel structural modifications described for siRNAs--in particular multi-target siRNAs--are reviewed.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24796432     DOI： 10.1089/nat.2014.0480

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN： 2159-3337            Impact factor:   5.486


  9 in total

1.  Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions.

Authors:  Kristin Derlig; Andreas Gießl; Johann Helmut Brandstätter; Ralf Enz; Regina Dahlhaus
Journal:  J Vis Exp       Date:  2016-04-21       Impact factor: 1.355

2.  Size unbiased representative enzymatically generated RNAi (SURER) library and application for RNAi therapeutic screens.

Authors:  Tiejun Li; York Yuanyuan Zhu; Li Chen; Yuncheng Sun; Jian Yuan; Michael Graham; Peter French
Journal:  Nucleic Acid Ther       Date:  2014-12-10       Impact factor: 5.486

Review 3.  Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment.

Authors:  James C Cummings; Haiwen Zhang; Andrew Jakymiw
Journal:  Transl Res       Date:  2019-07-29       Impact factor: 7.012

4.  A large-scale in vivo RNAi screen to identify genes involved in Notch-mediated follicle cell differentiation and cell cycle switches.

Authors:  Dongyu Jia; Muhammed Soylemez; Gabriel Calvin; Randy Bornmann; Jamal Bryant; Cameron Hanna; Yi-Chun Huang; Wu-Min Deng
Journal:  Sci Rep       Date:  2015-07-24       Impact factor: 4.379

5.  Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma.

Authors:  Tiejun Li; Yuwen Xue; Guilan Wang; Tingting Gu; Yunlong Li; York Yuanyuan Zhu; Li Chen
Journal:  J Cancer       Date:  2016-06-25       Impact factor: 4.207

6.  Preparation of a disulfide-linked precipitative soluble support for solution-phase synthesis of trimeric oligodeoxyribonucleotide 3´-(2-chlorophenylphosphate) building blocks.

Authors:  Amit M Jabgunde; Alejandro Gimenez Molina; Pasi Virta; Harri Lönnberg
Journal:  Beilstein J Org Chem       Date:  2015-09-07       Impact factor: 2.883

Review 7.  siRNA Versus miRNA as Therapeutics for Gene Silencing.

Authors:  Jenny K W Lam; Michael Y T Chow; Yu Zhang; Susan W S Leung
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-15       Impact factor: 10.183

8.  RNA interference-based functional knockdown of the voltage-gated potassium channel Kv7.2 in dorsal root ganglion neurons after in vitro and in vivo gene transfer by adeno-associated virus vectors.

Authors:  Markus Valdor; Anke Wagner; Viola Röhrs; Johanna Berg; Henry Fechner; Wolfgang Schröder; Thomas M Tzschentke; Gregor Bahrenberg; Thomas Christoph; Jens Kurreck
Journal:  Mol Pain       Date:  2017-12-06       Impact factor: 3.395

9.  Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells.

Authors:  Michael A Estrin; Islam T M Hussein; Wendy B Puryear; Anne C Kuan; Stephen C Artim; Jonathan A Runstadler
Journal:  PLoS One       Date:  2018-05-18       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.